Gemcitabine (Chemotherapy)

DRUG2 trials

Sponsors

Pharmexa A/S, Hoffmann-La Roche

Conditions

Advanced Unresectable Pancreatic CancerOvarian Cancer

Phase 3

GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Pancreatic Cancer

TerminatedNCT00358566

Pharmexa A/SAdvanced Unresectable Pancreatic Cancer

Start: 2006-06-30End: 2008-08-31Updated: 2008-05-19

Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)

CompletedNCT01684878

Hoffmann-La RocheOvarian Cancer

Start: 2012-10-22End: 2016-04-28Updated: 2017-05-23

Related Papers

Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer.

2019-08-159 citations

Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial.

2016-06-013 citations

Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum-resistant ovarian cancer (PROC): AGO-OVAR 2.20/ENGOT-ov14/PENELOPE double-blind placebo-controlled randomized phase III trial.

Journal of Clinical Oncology2015-05-206 citations

PENELOPE/AGO-OVAR 2.20: A double-blind placebo (PLA)-controlled randomized phase III ENGOT trial evaluating chemotherapy (CT) with or without pertuzumab (P) for platinum-resistant ovarian cancer.

Journal of Clinical Oncology2014-05-204 citations

Pertuzumab (P) plus chemotherapy (CT) for platinum-resistant ovarian cancer: Safety run-in results of the PENELOPE trial.

Journal of Clinical Oncology2014-05-201 citations